FGF1 has an unique ability to lower blood glucose, and pharmacologically-relevant FGF1 (0.5 mg/kg) leads to impressive changes in several measurements, including blood glucose, nearly normalizing after 35 days in T2D mice models with impaired insulin sensitivity (JaeMyoung et al., 2014). This evidence concerns the gene INS and type 2 diabetes mellitus.